# Real-world use of oral semaglutide in adults with type 2 diabetes.

> PubMed lists PMID 42592768 in Danish medical journal as Journal Article, Multicenter Study, with publication-date metadata of 2026-06-16 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-42592768-semaglutide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-08-13
- Source checked: 2026-08-13
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42592768-semaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/objects/pubmed-pmid-42592768-semaglutide-v1.json
- Content SHA-256: `97fe44fd62ac55bc8dbfa8aa9ea95bea2582d043ca8a4f86b7387f76b21ddde7`

## Claims and source pins

### Headline

Real-world use of oral semaglutide in adults with type 2 diabetes. ([`pubmed-observation-pmid-42592768-2026-08-13-05635b809594`](#source-pubmed-observation-pmid-42592768-2026-08-13-05635b809594))

### Summary

PubMed lists PMID 42592768 in Danish medical journal as Journal Article, Multicenter Study, with publication-date metadata of 2026-06-16 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42592768-2026-08-13-05635b809594`](#source-pubmed-observation-pmid-42592768-2026-08-13-05635b809594))

### Paragraph 1

PubMed lists PMID 42592768 in Danish medical journal as Journal Article, Multicenter Study, with publication-date metadata of 2026-06-16 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42592768-2026-08-13-05635b809594`](#source-pubmed-observation-pmid-42592768-2026-08-13-05635b809594))

### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42592768-2026-08-13-05635b809594`](#source-pubmed-observation-pmid-42592768-2026-08-13-05635b809594))

## Sources

<a id="source-pubmed-observation-pmid-42592768-2026-08-13-05635b809594"></a>
- **Real-world use of oral semaglutide in adults with type 2 diabetes. · retained source version 1:2026-08-13:current:05635b809594af79f3aa90a345784c8a1a39f1dd87f9a2500d0629c15bff6c7f** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42592768/) (`pubmed-observation-pmid-42592768-2026-08-13-05635b809594`)

## Correction lineage

No correction is recorded for this version.

## Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

## Suggested citation

PeptideScanner. "Real-world use of oral semaglutide in adults with type 2 diabetes." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/objects/pubmed-pmid-42592768-semaglutide-v1.json SHA-256: 97fe44fd62ac55bc8dbfa8aa9ea95bea2582d043ca8a4f86b7387f76b21ddde7.